Autologous hematopoietic stem cell transplantation (ASCT) outcomes in non-Hodgkin lymphoma (NHL) patients undergoing high dose therapy (HDT) with etoposide, cyclophosphamide and thiotepa (VP/CY/TT) versus cyclophosphamide, carmustine and etoposide (CBV)

被引：0
|
作者：
Veltri, L. W. [1 ]
Shah, N. [1 ]
Cumpston, A. [1 ]
Zhang, J. [1 ]
Wen, S. [1 ]
Watkins, K. [1 ]
Leadmon, S. [1 ]
Craig, M. [1 ]
Hamadani, M. [2 ]
Kanate, A. S. [1 ]
机构：
[1] W Virginia Univ, Hematol Oncol, Morgantown, WV 26506 USA
[2] Med Coll Wisconsin, Hematol Oncol, Milwaukee, WI 53226 USA
来源：
BONE MARROW TRANSPLANTATION | 2016年 / 51卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
P237
引用
收藏
页码：S238 / S238
页数：1
相关论文
共 50 条
  • [31] High-dose cyclophosphamide, BCNU, and VP-16 (CBV) conditioning before allogeneic stem cell transplantation for patients with non-Hodgkin's lymphoma
    H A Rossi
    P S Becker
    R V B Emmons
    P Westervelt
    W Levy
    Q Liu
    Y Clark
    K Ballen
    Bone Marrow Transplantation, 2003, 31 : 441 - 446
  • [32] AUTOLOGOUS STEM-CELL TRANSPLANTATION (ASCT) FOLLOWING BCNU, ETOPOSIDE, CYTARABINE AND CYCLOPHOSPHAMIDE (BVAC) FOR PATIENTS WITH RELAPSED LYMPHOMA
    BROCHSTEIN, JA
    PECORA, AL
    ZAHOS, K
    JENNIS, A
    VANVLIET, A
    GRAZIOSO, L
    CANTWELL, S
    MICHELIS, M
    ISAACS, R
    BLOOD, 1994, 84 (10) : A205 - A205
  • [33] Daily Weight-Based Busulfan with Cyclophosphamide and Etoposide (Bu/Cy/VP) Produces Comparable Outcomes to 4-Times-Daily Busulfan Dosing for Lymphoma Patients Undergoing Autologous Stem Cell Transplantation (ASCT)
    Hill, Brian T.
    Rybicki, Lisa A.
    Weber, Catherine
    Jagadeesh, Deepa
    Gerds, Aaron T.
    Hamilton, Betty K.
    Liu, Hien K.
    Dean, Robert M.
    Sobecks, Ronald M.
    Pohlman, Brad
    Andresen, Steven
    Kalaycio, Matt
    Bolwell, Brian J.
    Majhail, Navneet S.
    BLOOD, 2015, 126 (23)
  • [34] High-dose cyclophosphamide, BCNU, and VP-16 (CBV) conditioning before allogeneic stem cell transplantation for patients with non-Hodgkin's lymphoma
    Rossi, HA
    Becker, PS
    Emmons, RVB
    Westervelt, P
    Levy, W
    Liu, Q
    Clark, Y
    Ballen, K
    BONE MARROW TRANSPLANTATION, 2003, 31 (06) : 441 - 446
  • [35] Thiotepa, busulfan, and cyclophosphamide or busulfan, cyclophosphamide, and etoposide high-dose chemotherapy followed by autologous stem cell transplantation for consolidation of primary central nervous system lymphoma
    Hyung, Jaewon
    Hong, Jung Yong
    Yoon, Dok Hyun
    Kim, Shin
    Park, Jung Sun
    Park, Chan-sik
    Lee, Sang-wook
    Kim, Jeong Hoon
    Ryu, Jin Sook
    Huh, Jooryung
    Suh, Cheolwon
    ANNALS OF HEMATOLOGY, 2019, 98 (07) : 1657 - 1664
  • [36] Evaluation of busulfan, cyclophosphamide, and etoposide as a preparation regimen for autologous stem cell transplantation in Hodgkin's lymphoma patients
    Bicim, Soykan
    Erkurt, Mehmet Ali
    Kuku, Irfan
    Kaya, Emin
    Berber, Ilhami
    Kaya, Ahmet
    Hidayet, Emine
    Uysal, Ayse
    Sarici, Ahmet
    Ozen, Ilknur Nizam
    IRAQI JOURNAL OF HEMATOLOGY, 2024, 13 (01) : 1 - 6
  • [37] Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin's disease
    Reece, DE
    Nevill, TJ
    Sayegh, A
    Spinelli, JJ
    Brockington, DA
    Barnett, MJ
    Klingemann, HG
    Connors, JM
    Nantel, SH
    Shepherd, JD
    Sutherland, HJ
    Voss, NJS
    Fairey, RN
    O'Reilly, SE
    Phillips, GL
    BONE MARROW TRANSPLANTATION, 1999, 23 (11) : 1131 - 1138
  • [38] Thiotepa, busulfan, and cyclophosphamide or busulfan, cyclophosphamide, and etoposide high-dose chemotherapy followed by autologous stem cell transplantation for consolidation of primary central nervous system lymphoma
    Jaewon Hyung
    Jung Yong Hong
    Dok Hyun Yoon
    Shin Kim
    Jung Sun Park
    Chan-sik Park
    Sang-wook Lee
    Jeong Hoon Kim
    Jin Sook Ryu
    Jooryung Huh
    Cheolwon Suh
    Annals of Hematology, 2019, 98 : 1657 - 1664
  • [39] Impact of intensive stem cell mobilization therapy on outcomes following autologous stem cell transplantation (ASCT) for non-Hodgkin lymphoma (NHL)
    Damon, L. E.
    Damon, L.
    Kaplan, L.
    Martin, T., III
    Linker, C. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [40] Late relapses following autologous hematopoietic stem cell (ASCT) transplantation for non-Hodgkin's lymphoma (NHL).
    Bierman, PJ
    Vose, JM
    Lynch, JC
    Bociek, RG
    Morris, ME
    Armitage, JO
    BLOOD, 1999, 94 (10) : 610A - 610A
12345